{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:59:40Z","timestamp":1786982380383,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T00:00:00Z","timestamp":1708732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T00:00:00Z","timestamp":1708732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014064","name":"Universidad de Salamanca","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014064","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s12325-024-02797-x","type":"journal-article","created":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T14:01:58Z","timestamp":1708783318000},"page":"1576-1593","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed\/Refractory Multiple Myeloma"],"prefix":"10.1007","volume":"41","author":[{"given":"Hermann","family":"Einsele","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar","family":"Bahlis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Bhutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Karlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Perrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels W. C. J.","family":"van de Donk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique M.","family":"Ocio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquin","family":"Martinez-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Rodr\u00edguez-Otero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Dytfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joris","family":"Diels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadim","family":"Strulev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imene","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Renaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Ammann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jedelyn","family":"Cabrieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nolen","family":"Perualila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trilok","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Victoria","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,24]]},"reference":[{"issue":"5","key":"2797_CR1","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/ajh.25791","volume":"95","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(5):548\u201367.","journal-title":"Am J Hematol"},{"key":"2797_CR2","doi-asserted-by":"crossref","first-page":"117822421986823","DOI":"10.1177\/1178224219868235","volume":"13","author":"SA Bird","year":"2019","unstructured":"Bird SA, Boyd K. Multiple myeloma: an overview of management. Palliat Care Soc Pract. 2019;13:1178224219868235.","journal-title":"Palliat Care Soc Pract"},{"key":"2797_CR3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.leukres.2017.05.019","volume":"59","author":"C Hulin","year":"2017","unstructured":"Hulin C, Hansen T, Heron L, et al. Living with the burden of relapse in multiple myeloma from the patient and physician perspective. Leuk Res. 2017;59:75\u201384.","journal-title":"Leuk Res"},{"issue":"1","key":"2797_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clml.2019.09.621","volume":"20","author":"J Mikhael","year":"2020","unstructured":"Mikhael J. Treatment options for triple-class refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2020;20(1):1\u20137.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"14","key":"2797_CR5","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1200\/JCO.18.02096","volume":"37","author":"J Mikhael","year":"2019","unstructured":"Mikhael J, Ismaila N, Cheung MC, et al. Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline. J Clin Oncol. 2019;37(14):1228\u201363.","journal-title":"J Clin Oncol"},{"key":"2797_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100808","volume":"49","author":"K Ramasamy","year":"2021","unstructured":"Ramasamy K, Gay F, Weisel K, Zweegman S, Mateos MV, Richardson P. Improving outcomes for patients with relapsed multiple myeloma: challenges and considerations of current and emerging treatment options. Blood Rev. 2021;49: 100808.","journal-title":"Blood Rev"},{"issue":"3","key":"2797_CR7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41408-018-0065-8","volume":"8","author":"P Ravi","year":"2018","unstructured":"Ravi P, Kumar SK, Cerhan JR, et al. Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. Blood Cancer J. 2018;8(3):26.","journal-title":"Blood Cancer J"},{"issue":"9","key":"2797_CR8","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","volume":"33","author":"UH Gandhi","year":"2019","unstructured":"Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33(9):2266\u201375.","journal-title":"Leukemia"},{"issue":"5","key":"2797_CR9","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","volume":"36","author":"MV Mateos","year":"2022","unstructured":"Mateos MV, Weisel K, De Stefano V, et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma. Leukemia. 2022;36(5):1371\u20136.","journal-title":"Leukemia"},{"issue":"15","key":"2797_CR10","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1182\/blood.2019003342","volume":"135","author":"K Pillarisetti","year":"2020","unstructured":"Pillarisetti K, Edavettal S, Mendonca M, et al. A T-cell-redirecting bispecific G-protein-coupled receptor class\u00a05 member D \u00d7 CD3 antibody to treat multiple myeloma. Blood. 2020;135(15):1232\u201343.","journal-title":"Blood"},{"issue":"7","key":"2797_CR11","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.3390\/jcm9072166","volume":"9","author":"X Zhou","year":"2020","unstructured":"Zhou X, Einsele H, Danhof S. Bispecific antibodies: a new era of treatment for multiple myeloma. J Clin Med. 2020;9(7):2166.","journal-title":"J Clin Med"},{"key":"2797_CR12","unstructured":"TALVEY (talquetamab-tgvs). Prescribing information. Horsham, PA: Janssen Biotech, Inc."},{"issue":"24","key":"2797_CR13","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG, et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387(24):2232\u201344.","journal-title":"N Engl J Med"},{"issue":"16_suppl","key":"2797_CR14","doi-asserted-by":"publisher","first-page":"8015","DOI":"10.1200\/JCO.2022.40.16_suppl.8015","volume":"40","author":"MC Minnema","year":"2022","unstructured":"Minnema MC, Krishnan AY, Berdeja JG, et al. Efficacy and safety of talquetamab, a G protein-coupled receptor family C group\u00a05 member D \u00d7 CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM): Updated results from MonumenTAL-1. J Clin Oncol. 2022;40(16_suppl):8015.","journal-title":"J Clin Oncol"},{"issue":"12","key":"2797_CR15","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1002\/ajh.25963","volume":"95","author":"BGM Durie","year":"2020","unstructured":"Durie BGM, Kumar SK, Usmani SZ, et al. Daratumumab-lenalidomide-dexamethasone vs standard-of-care regimens: efficacy in transplant-ineligible untreated myeloma. Am J Hematol. 2020;95(12):1486\u201394.","journal-title":"Am J Hematol"},{"key":"2797_CR16","unstructured":"clinicaltrials.gov. A study of real-life current standards of care in participants with relapsed and\/or refractory multiple myeloma (MoMMent). (NCT05160584). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05160584. Accessed Feb 08, 2023."},{"issue":"8","key":"2797_CR17","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328\u201346.","journal-title":"Lancet Oncol"},{"issue":"521","key":"2797_CR18","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1080\/01621459.2016.1260466","volume":"113","author":"F Li","year":"2018","unstructured":"Li F, Morgan KL, Zaslavsky AM. Balancing covariates via propensity score weighting. J Am Stat Assoc. 2018;113(521):390\u2013400.","journal-title":"J Am Stat Assoc"},{"issue":"25","key":"2797_CR19","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083\u2013107.","journal-title":"Stat Med"},{"issue":"3","key":"2797_CR20","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011;46(3):399\u2013424.","journal-title":"Multivar Behav Res"},{"issue":"2","key":"2797_CR21","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/pst.433","volume":"10","author":"PC Austin","year":"2011","unstructured":"Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10(2):150\u201361.","journal-title":"Pharm Stat"},{"issue":"6","key":"2797_CR22","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1001\/jama.2018.21554","volume":"321","author":"S Haneuse","year":"2019","unstructured":"Haneuse S, VanderWeele TJ, Arterburn D. Using the E-value to assess the potential effect of unmeasured confounding in observational studies. JAMA. 2019;321(6):602\u20133.","journal-title":"JAMA"},{"issue":"1","key":"2797_CR23","doi-asserted-by":"publisher","first-page":"3500","DOI":"10.1038\/s41467-022-30908-1","volume":"13","author":"S Popat","year":"2022","unstructured":"Popat S, Liu SV, Scheuer N, et al. Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of pralsetinib in non-small cell lung cancer. Nat Commun. 2022;13(1):3500.","journal-title":"Nat Commun"},{"issue":"4","key":"2797_CR24","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167(4):268\u201374.","journal-title":"Ann Intern Med"},{"issue":"10297","key":"2797_CR25","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase\u00a01b\/2 open-label study. Lancet. 2021;398(10297):314\u201324.","journal-title":"Lancet"},{"issue":"5","key":"2797_CR26","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1007\/s12325-023-02480-7","volume":"40","author":"P Moreau","year":"2023","unstructured":"Moreau P, van de Donk N, Delforge M, et al. Comparative efficacy of teclistamab versus current treatments in real-world clinical practice in the prospective LocoMMotion study in patients with triple-class-exposed relapsed and\/or refractory multiple myeloma. Adv Ther. 2023;40(5):2412\u201325.","journal-title":"Adv Ther"},{"issue":"8","key":"2797_CR27","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705\u201316.","journal-title":"N Engl J Med"},{"issue":"1","key":"2797_CR28","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1080\/10428194.2018.1459609","volume":"60","author":"S Kumar","year":"2019","unstructured":"Kumar S, Durie B, Nahi H, et al. Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma. Leuk Lymphoma. 2019;60(1):163\u201371.","journal-title":"Leuk Lymphoma"},{"issue":"15","key":"2797_CR29","doi-asserted-by":"publisher","first-page":"3139","DOI":"10.1182\/blood-2009-03-201053","volume":"114","author":"JL Harousseau","year":"2009","unstructured":"Harousseau JL, Attal M, Avet-Loiseau H. The role of complete response in multiple myeloma. Blood. 2009;114(15):3139\u201346.","journal-title":"Blood"},{"key":"2797_CR30","doi-asserted-by":"publisher","unstructured":"Delforge M, Moreau P, Einsele H, et al. Health-related quality of life (HRQoL) in patients with relapsed\/refractory multiple myeloma (RRMM) receiving real-life current standard of care (SOC) in the LocoMMotion study. J Clin Oncol. 2020;40(16_suppl):8030. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.80.","DOI":"10.1200\/JCO.2022.40.16_suppl.80"},{"key":"2797_CR31","unstructured":"FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma [press release]. U.S. Food and Drug Administration. 2022."},{"key":"2797_CR32","unstructured":"European Medicines Agency. TECVAYLI (teclistamab). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tecvayli. Accessed 5 Oct 2023."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02797-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02797-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02797-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T05:36:06Z","timestamp":1711172166000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02797-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,24]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["2797"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02797-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,24]]},"assertion":[{"value":"11 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hermann Einsele has received honoraria from Amgen, BMS, EUSA Pharma, Genesis, GSK, Janssen, Novartis, Sanofi, and Takeda, travel expenses from Amgen, EUSA Pharma, and Takeda and research funding from Amgen, Genesis, GSK, Janssen, Sanofi, and Takeda. Philippe Moreau has served in a consulting or advisory role and received honoraria from AbbVie, Amgen, Celgene, GSK, Janssen, Oncopeptides, and Sanofi. Nizar Bahlis has a consulting or advisory role with AbbVie, Amgen, BMS, Forus, GSK, Janssen, Pfizer, Sanofi, and Takeda, received honoraria from AbbVie, Amgen, BMS, Forus, Janssen, and Sanofi, has been a member of the steering committee at AbbVie, GSK, and Janssen and has received research funding from Janssen and Pfizer. Manisha Bhutani has received funding from Adaptive Biotechnologies, Amgen, Bluebird Bio, Bristol Myers Squibb\/Celgene, Celularity Inc., Cerecor, Janssen, Legend Biotech, MedImmune, and Takeda. Laure Vincent has received funding from Janssen, honoraria from BMS and Janssen, travel expenses from Amgen, BMS, GSK, Janssen, Sanofi, and Takeda, and has participated on an advisory board for BMS, Janssen, and Takeda. Lionel Karlin has served in a consulting or advisory role and received honoraria from Amgen, BMS\/Celgene, GSK, Janssen, Sanofi, Stemline, and Takeda, has received travel expenses from Amgen, BMS\/Celgene, Janssen, Sanofi, and Takeda, and has an immediate family member employed by Laoratoira Aguettant. Aurore Perrot has received honoraria or served a consulting role with AbbVie, Amgen, BMS, Janssen, Pfizer, Sanofi, and Takeda. Hartmut Goldschmidt has served in a consulting or advisory role for Adaptive Biotechnologies, Amgen, BMS, Celgene, Janssen-Cilag, Sanofi, and Takeda, received travel funding from Janssen-Cilag and Sanofi, honoraria from Amgen, BMS, Celgene, Chugai Pharma, GSK, Janssen-Cilag, Novartis, and Sanofi, research funding from Amgen, BMS, Celgene, Chugai Pharma Europe, Incyte, Janssen, Molecular Partners, MSD, Mundipharma, Novartis, and Takeda, and discloses other relationships with Amgen, Celgene\/BMS, Chugai Pharma Europe, Janssen, and Sanofi. Niels WCJ van de Donk has received research support from Amgen, Bristol Myers Squibb, Celgene, Cellectis, Janssen Pharmaceuticals, and Novartis, and serves on advisory boards for AbbVie, Adaptive, Amgen, Bayer, Bristol Myers Squibb, Celgene, Janssen Pharmaceuticals, Novartis, Pfizer, Roche, Servier, and Takeda (all paid to their institution). Enrique M Ocio, Joaquin Martinez Lopez, Paula Rodr\u00edguez-Otero, Dominik Dytfeld, Joris Diels, Vadim Strulev, Imene Haddad, Thomas Renaud, Eric Ammann, Jedelyn Cabrieto, Nolen Perualila, Ryan Gan, Youyi Zhang, Trilok Parekh, and Claire Albrecht are employees of Janssen and may own stock in Johnson & Johnson\/Janssen. Katja Weisel has served in a consulting or advisory role for Adaptive Biotechnologies, Amgen, BMS, Celgene, GSK, Janssen-Cilag, Karyopharm Therapeutics, Oncopeptides, Roche, Sanofi, and Takeda, received travel, accommodations, and\/or expenses from Amgen, BMS, Celgene, GSK, Janssen-Cilag, and Takeda, honoraria from AbbVie, Adaptive Biotechnologies, Amgen, BMS, Celgene, GSK, Janssen-Cilag, Karyopharm Therapeutics, Novartis, Oncopeptides, Pfizer, Roche\/Genentech, Sanofi, and Takeda, and research funding from Amgen, BMS, Celgene, GSK, Janssen-Cilag, and Sanofi. Maria-Victoria Mateos has served in a consulting or advisory role for AbbVie, Amgen, Celgene, GSK, Janssen-Cilag, Pfizer, Regeneron, Roche\/Genentech, and Takeda, and received honoraria from AbbVie\/Genentech, Amgen, Celgene, GSK, Janssen-Cilag, Sanofi, and Takeda.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Data analyzed in this study were received from the MonumenTAL-1, LocoMMotion, and MoMMent studies. MonumenTAL-1 was conducted in accordance with the Declaration of Helsinki and International Conference on Harmonisation Guidelines for Good Clinical Practice. All patients provided written informed consent. An independent ethics committee or institutional review board at each study center approved the study protocol (Supplementary Materials Tables\u00a0\n                      \n                      \u2013S3). The LocoMMotion and MoMMent studies were conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent. An independent ethics committee\/institutional review board at each center approved the study protocol.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}